Free tool
FAERS Monitor: Palynziq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761079 or its brand name (Palynziq, Pegvaliase-Pqpz). Reports on generic versions are filed under their own applications.
Reports
8,518
Serious
1,340
16% of reports
Hospitalization
314
Death reported
12
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- arthralgia1,463
- injection site reaction957
- injection site erythema794
- injection site swelling584
- rash533
- urticaria523
- headache461
- injection site pain448
- injection site pruritus389
- fatigue386
- pruritus359
- hypersensitivity357
- dizziness347
- nausea342
- anaphylactic reaction337
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 156 |
| 2019 | 1,038 |
| 2020 | 1,207 |
| 2021 | 1,114 |
| 2022 | 860 |
| 2023 | 1,027 |
| 2024 | 1,148 |
| 2025 | 1,082 |
| 2026 | 886 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,641 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| injection site reactionSignal | 957 | 34.8 | 32.8 | 31,059 |
| injection site swellingSignal | 584 | 19.0 | 17.5 | 9,876 |
| injection site erythemaSignal | 794 | 15.9 | 14.9 | 11,066 |
| anaphylactic reactionSignal | 337 | 15.1 | 13.6 | 4,423 |
| injection site pruritusSignal | 389 | 14.4 | 13.1 | 4,831 |
| arthralgiaSignal | 1,463 | 8.7 | 8.3 | 10,150 |
| urticariaSignal | 523 | 7.7 | 7.1 | 3,072 |
| hypersensitivitySignal | 357 | 4.8 | 4.3 | 1,063 |
| injection site painSignal | 448 | 3.6 | 3.3 | 854 |
| rashSignal | 533 | 3.0 | 2.8 | 733 |
| pruritusSignal | 359 | 2.3 | 2.1 | 269 |
| headache | 461 | 1.8 | 1.7 | 173 |
| dizziness | 347 | 1.7 | 1.6 | 106 |
| fatigue | 386 | 1.2 | 1.1 | 16 |
| nausea | 342 | 1.1 | 1.0 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.